Ventilatory Threshold and Risk of Pulmonary Exacerbations in Cystic Fibrosis

被引:0
|
作者
Campos, Natalia E. [1 ]
Vendrusculo, Fernanda M. [1 ]
Perez-Ruiz, Margarita [2 ]
Donadio, Marcio V. F. [1 ,3 ,4 ]
机构
[1] Pontificia Univ Catolica Rio Grande do Sul, Infant Ctr, Lab Pediat Phys Act, Porto Alegre, RS, Brazil
[2] Univ Politecn Madrid, Fac Ciencias Act Fis & Deporte, Dept Hlth & Human Performance, Madrid, Spain
[3] Univ Int Catalunya, Fac Med & Ciencias Salud, Dept Physiotherapy, Barcelona, Spain
[4] Ctr Infant, Lab Pediat Phys Act, Av Ipiranga 6690,2 Andar, BR-90610000 Porto Alegre, RS, Brazil
关键词
  cystic fibrosis; pulmonary exacerbation; anaerobic threshold; exercise capacity; prognosis; oxygen consumption; QUALITY-OF-LIFE; HEART-FAILURE; NUTRITIONAL-STATUS; PEAK VO2; CHILDREN; HOSPITALIZATION; STANDARDIZATION; ABNORMALITIES; SPIROMETRY; FREQUENCY;
D O I
10.4187/respcare.10428
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Whereas pulmonary exacerbations and aerobic fitness play a key role in the prognosis of cystic fibrosis (CF), the use of ventilatory threshold data as markers of exacerbation risk has been scarcely addressed. This study sought to examine the association between aerobic fit-ness, assessed through ventilatory threshold variables recorded during cardiopulmonary exercise testing (CPET), and the risk of exacerbations in individuals with CF. METHODS: Participants of this retrospective cohort study were subjects from 6 y of age. Over a 4-y period, the following data were recorded: lung function indicators, CPET variables, time to first exacerbation and an-tibiotic use, along with demographic, clinical, and anthropometric data. RESULTS: The mean age of 20 subjects included was 16 +/- 5.4 y. Univariate regression analysis revealed that lung function (FEV1: Cox hazard ratio [HR] 0.97, P = .03; and forced expiratory flow between 25- 75% of vital capacity [FEF25-75]: Cox HR 0.98, P = .036) and aerobic fitness (oxygen consump-tion [VO2] at ventilatory threshold: Cox HR 0.94, P = .01; and ventilatory equivalent for carbon dioxide [VE/VCO2] at ventilatory threshold: Cox HR 1.13, P = .049) were associated with exacerba-tion risk, whereas in the multivariate model, only VO2 at the ventilatory threshold (%max) (Cox HR 0.92, P = .01) had a significant impact on this risk. Consistently, individuals experiencing exacerba-tion had significantly lower VO2 values (%max) at the ventilatory threshold (P = .050) and higher ventilatory equivalent for oxygen consumption (VE/VO2) (P = .040) and VE/VO2 (P = .037) values at the ventilatory threshold. Time to exacerbation was significantly correlated with VO2 at the ventila-tory threshold (r = 0.50, P = .02), VE/VO2 (r = -0.48, P = .02), and VE/VCO2 (r = -0.50, P = .02). CONCLUSIONS: Our results suggest an association between CPET variables at the ventila-tory threshold and exacerbations. Percentage VO2 at the ventilatory threshold could serve as a complementary variable to monitor exacerbations in people with CF.
引用
收藏
页码:620 / 627
页数:8
相关论文
共 50 条
  • [41] Vitamin D serum level and pulmonary exacerbations in children with cystic fibrosis
    Butenko, Tita
    Rodman, Jasna
    Praprotnik, Marina
    Aldeco, Malena
    Lepej, Dusanka
    Krivec, Uros
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [42] Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis
    Wagener, Jeffrey S.
    Williams, Michael J.
    Millar, Stefanie J.
    Morgan, Wayne J.
    Pasta, David J.
    Konstan, Michael W.
    JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (04) : 496 - 502
  • [43] Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients
    Waters, Valerie J.
    Stanojevic, Sanja
    Sonneveld, Nicole
    Klingel, Michelle
    Grasemann, Haitmut
    Yau, Yvonne C. W.
    Tullis, Elizabeth
    Wilcox, Pearce
    Freitag, Andreas
    Chilvers, Mark
    Ratjen, Felix A.
    JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (06) : 755 - 762
  • [44] Impact of viral respiratory infections on pulmonary exacerbations in children with cystic fibrosis
    Gonzalez-Rosales, Noel
    Kasi, Ajay S. S.
    McCracken, Courtney E. E.
    Silva, George L. L.
    Starks, Miah
    Stecenko, Arlene
    Guglani, Lokesh
    PEDIATRIC PULMONOLOGY, 2023, 58 (03) : 871 - 877
  • [45] Pulmonary Exacerbations in Cystic Fibrosis With Negative Bacterial Cultures
    Zemanick, Edith T.
    Wagner, Brandie D.
    Harris, J. Kirk
    Wagener, Jeffery S.
    Accurso, Frank J.
    Sagel, Scott D.
    PEDIATRIC PULMONOLOGY, 2010, 45 (06) : 569 - 577
  • [46] Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations
    L. Keith Scott
    Robert Toner
    Lung, 2017, 195 : 397 - 401
  • [47] Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations
    Waters, Valerie
    Stanojevic, Sanja
    Klingel, Michelle
    Chiang, Jackie
    Sonneveld, Nicole
    Kukkar, Richa
    Tullis, Elizabeth
    Ratjen, Felix
    JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (06) : 770 - 776
  • [48] SPLUNC1 in sputum of children with cystic fibrosis pulmonary exacerbations
    Ben-Meir, Elad
    Perrem, Lucy
    Ratjen, Felix
    Grasemann, Hartmut
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [49] Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis
    Fireizen, Yaron
    Ahmed, Mohamoud
    Vigers, Timothy
    Akong, Kathryn
    Ryu, Julie
    Hahn, Andrea
    Fanous, Hani
    Koumbourlis, Anastassios
    Tirakitsoontorn, Pornchai
    Arrieta, Antonio
    Burgener, Elizabeth B.
    Koff, Jonathan
    Cogen, Jonathan D.
    Bouzek, Drake C.
    Hanley, Elin
    Keck, Allison
    Stout, Dayna
    Bradley, John
    Sagel, Scott D.
    PEDIATRIC PULMONOLOGY, 2025, 60 (03)
  • [50] Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis
    McElvaney, Oliver J.
    Heltshe, Sonya L.
    Odem-Davis, Katherine
    West, Natalie E.
    Sanders, Don B.
    Fogarty, Barbra
    VanDevanter, Donald R.
    Flume, Patrick A.
    Goss, Christopher H.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2024, 21 (05) : 716 - 726